http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113088489-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-515 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-51 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-2302 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-2315 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-2307 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-15 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01N1-0221 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0634 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01N1-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-078 |
| filingDate | 2021-04-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-01-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-01-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-113088489-B |
| titleOfInvention | Initial immune cell activation and amplification system and application thereof |
| abstract | The invention relates to the technical field of immune cell therapy, in particular to an initial immune cell activation and amplification system and application thereof. The invention provides an initial immune cell activation and amplification system, wherein a TGF-beta antagonist is added into an activation medium, the TGF-beta antagonist is competitively combined with TGF-beta R on the surface of a T cell in a peripheral blood mononuclear cell, the combination of TGF-beta and TGF-beta R is blocked, a TGF-beta mediated signal channel is inhibited, the number and the function of Treg cells which are abnormally increased are reduced, the functional activity and the amplification capacity of T effector cells and antigen presenting cells are up-regulated, the insufficient number and the reduced function of the initial immune cells caused by negative immune regulation and control mechanisms such as TGF-beta up-regulation of the Treg cells and the like are avoided, and high-quality and high-quantity excellent seed cells are provided for the later-stage successful preparation of targeted immune cells. The invention also provides a method for activating and expanding the initial immune cells and a method for preparing the target immune cells. |
| priorityDate | 2021-04-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 113.